Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction
Basic & Clinical Pharmacology & Toxicology · 2023-12 · 133 (6) · 757-769
DOI: 10.1111/bcpt.13947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 18.10.2023. Verfasst von Enxue Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Second Hospital, Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Ureteral Obstruction, Berberine, Kidney Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Berberine acts via multiple pathways to alleviate fibrosis in various tissues and shows renoprotective effects. However, its role and underlying mechanisms in renal fibrosis remain unclear. Herein, we aimed to investigate the protective effects and molecular mechanisms of berberine against unilateral ureteric obstruction‐induced renal fibrosis. The results indicated that berberine treatment (50 mg/kg/day) markedly alleviated histopathological alterations, collagen deposition and inflammatory cell infiltration in kidney tissue and restored mouse renal function. Mechanistically, berberine intervention inhibited NOD‐like receptor family pyrin domain‐containing 3 (NLRP3) inflammasome activation and the levels of the inflammatory cytokine IL‐1β in the kidneys of unilateral ureteric obstruction mice. In addition, berberine relieved unilateral ureteric obstruction‐induced renal injury by activating adenosine monophosphate‐activated protein kinase (AMPK) signalling and promoting fatty acid β‐oxidation. In vitro models showed that berberine treatment prevented the TGF‐β1‐induced profibrotic phenotype of hexokinase 2 (HK‐2) cells, characterized by loss of an epithelial phenotype (alpha smooth muscle actin [α‐SMA]) and acquisition of mesenchymal marker expression (E‐cadherin), by restoring abnormal fatty acid β‐oxidation and upregulating the expression of the fatty acid β‐oxidation related‐key enzymes or regulators (phosphorylated‐AMPK, peroxisome proliferator activated receptor alpha [PPARα] and carnitine palmitoyltransferase 1A [CPT1A]). Collectively, berberine alleviated renal fibrosis by inhibiting NLRP3 inflammasome activation and protected tubular epithelial cells by reversing defective fatty acid β‐oxidation. Our findings might be exploited clinically to provide a potential novel therapeutic strategy for renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Second Hospital, Shanxi Medical University, Taiyuan, China.
- Department of Nephrology, Shanxi Bethune Hospital, Taiyuan, China.
- Department of Cardiac Surgery, Shanxi Cardiovascular Hospital, Taiyuan, China.
ORCID-Profile: Enxue Tan, Yanjuan Hou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tan, E., Gao, Z., Wang, Q., Han, B., Shi, H., Wang, L., Zhu, G., & Hou, Y. (2023). Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction. Basic & Clinical Pharmacology & Toxicology, 133(6), 757-769. https://doi.org/10.1111/bcpt.13947
Vancouver
Tan E, Gao Z, Wang Q, Han B, Shi H, Wang L, et al. Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction. Basic & Clinical Pharmacology & Toxicology. 2023;133(6):757-769. doi:10.1111/bcpt.13947
BibTeX
@article{Tan2023,
author = {Tan, Enxue and Gao, Zhihong and Wang, Qian and Han, Baosheng and Shi, Honghong and Wang, Lihua and Zhu, Guozhen and Hou, Yanjuan},
title = {Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
volume = {133},
number = {6},
pages = {757--769},
doi = {10.1111/bcpt.13947}
}
EUVIMED